Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
V-RBAC in high-risk elderly patients with mantle cell lymphoma
2017-004628-31Phase 2Active
- Sponsor
- Fondazione Italiana Linfomi
- Start
- Mar 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of venetoclax in mantle cell lymphoma (MCL), sponsored by Fondazione Italiana Linfomi. Primary endpoint: 2-year progression-free survival. Started Mar 2018; status: active.
02
Drugs
venetoclax
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on 2017-004628-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004628-31.